XASXRAC
Market cap149mUSD
Dec 27, Last price
1.38AUD
1D
0.00%
1Q
-22.47%
Jan 2017
626.32%
IPO
441.18%
Name
Race Oncology Ltd
Chart & Performance
P/E
—
P/S
59.88
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
15.55%
Rev. gr., 5y
77.30%
Revenues
4m
+27.73%
Net income
-14m
L+39.26%
CFO
-10m
L-10.38%
Earnings
Feb 26, 2025
Profile
Race Oncology Limited operates as a precision oncology company in Australia. The company is developing Zantrene, a potent small molecule inhibitor of the fatso/fat mass and obesity associated protein to treat for melanoma and clear cell renal cell carcinoma, as well as acute myeloid leukaemia, breast, and ovarian cancers, which is in Phase II/III clinical trial. It has a preclinical research program with the University of Newcastle for investigating Zantrene; and strategic collaboration with the University of Wollongong to evaluate Zantrene formulations. The company was formerly known as Coronado Resources Limited and changed its name to Race Oncology Limited in July 2016. Race Oncology Limited was incorporated in 2011 and is based in Sydney, Australia.
Valuation
Title AUD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024‑06 | 2023‑06 | 2022‑06 | 2021‑06 | 2020‑06 | 2019‑06 | 2018‑06 | 2017‑06 | 2016‑06 | 2015‑12 | 2015‑06 | |
| Income | |||||||||||
Revenues | 4,003 27.73% | 3,134 342.83% | 708 82.71% | ||||||||
Cost of revenue | 14,936 | 9,724 | 6,904 | ||||||||
Unusual Expense (Income) | |||||||||||
NOPBT | (10,933) | (6,590) | (6,196) | ||||||||
NOPBT Margin | |||||||||||
Operating Taxes | (4,003) | (3,134) | (708) | ||||||||
Tax Rate | |||||||||||
NOPAT | (6,929) | (3,456) | (5,489) | ||||||||
Net income | (13,819) 39.26% | (9,923) -11.41% | (11,202) 76.68% | ||||||||
Dividends | |||||||||||
Dividend yield | |||||||||||
Proceeds from repurchase of equity | 5,209 | (1,283) | 30,051 | ||||||||
BB yield | -1.73% | 0.65% | -10.05% | ||||||||
| Debt | |||||||||||
Debt current | |||||||||||
Long-term debt | |||||||||||
Deferred revenue | |||||||||||
Other long-term liabilities | 48 | ||||||||||
Net debt | (17,189) | (21,520) | (33,541) | ||||||||
| Cash flow | |||||||||||
Cash from operating activities | (9,546) | (10,652) | (6,258) | ||||||||
CAPEX | (1) | ||||||||||
Cash from investing activities | 7,900 | (1) | |||||||||
Cash from financing activities | 5,209 | (1,283) | 30,514 | ||||||||
FCF | (6,057) | (4,328) | (4,744) | ||||||||
| Balance | |||||||||||
Cash | 17,189 | 21,520 | 33,541 | ||||||||
Long term investments | |||||||||||
Excess cash | 16,989 | 21,364 | 33,505 | ||||||||
Stockholders' equity | 18,312 | 25,486 | 36,107 | ||||||||
Invested Capital | 1,372 | 4,122 | 2,602 | ||||||||
ROIC | |||||||||||
ROCE | |||||||||||
| EV | |||||||||||
Common stock shares outstanding | 164,501 | 160,721 | 153,310 | ||||||||
Price | 1.83 48.78% | 1.23 -36.92% | 1.95 -46.87% | ||||||||
Market cap | 301,036 52.28% | 197,686 -33.87% | 298,954 -37.80% | ||||||||
EV | 283,847 | 176,166 | 265,413 | ||||||||
EBITDA | (10,652) | (6,309) | (5,915) | ||||||||
EV/EBITDA | |||||||||||
Interest | |||||||||||
Interest/NOPBT | |||||||||||